Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from PreveCeutical Medical ( (TSE:PREV) ).
PreveCeutical Medical Inc. has announced a new program to develop its Sol-Gel Nose to Brain (N2B) delivery platform for treating Parkinson’s Disease. This program aims to deliver Dopamine and/or L-Dopa directly to the brain, potentially reducing side effects and improving patient outcomes by bypassing the Blood Brain Barrier. The company intends to explore partnerships once proof of concept is established in a preclinical model, underscoring its commitment to cost-effective therapeutic development and positioning itself favorably within the health sciences industry.
More about PreveCeutical Medical
PreveCeutical is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature identical products. The company aims to be a leader in the preventive health sciences sector.
YTD Price Performance: 5.56%
Average Trading Volume: 126,001
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.44M
See more data about PREV stock on TipRanks’ Stock Analysis page.
